Enzalutamide In The Non-Metastatic Setting For Crpc

Enzalutamide in the non-metastatic setting for CRPC

Enzalutamide in the Context of Nonmetastatic CRPC

Dr. Gomella on the FDA Approval of Enzalutamide in Nonmetastatic CRPC

An Update on the PROSPER Trial: Focusing on Nonmetastatic CRPC

Grand Rounds in Urology

The Future of Treatment for Nonmetastatic CRPC

Nonmetastatic CRPC: Considerations for Apalutamide

Understanding Nonmetastatic CRPC: An Overview

Head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic CRPC

A. Edward Yen - Prostate Cancer Highlights from GU ASCO and ASCO 2024

Grand Rounds in Urology

Dr. Wise on the FDA Approval of Apalutamide in Non-Metastatic CRPC

Dr. Dorff on Choosing Between Therapies in Nonmetastatic CRPC

Dr. Bradley on Impact of SPARTAN and PROSPER in Nonmetastatic CRPC

Dr. Plimack Discusses Trials Investigating Apalutamide, Enzalutamide in M0 CRPC

Awaiting key results for enzalutamide and apalutamide in nmCRPC

Clinical Trials in Non-Metastatic CRPC

Delaying disease progression in early, non-metastatic CRPC treatment

Dr. Gomella on the FDA Approval of Apalutamide for Nonmetastatic CRPC

Live long and PROSPER: enzalutamide for nmCRPC

Apalutamide: A Next-Gen Agent for Nonmetastatic CRPC

Approaching the Treatment of Nonmetastatic CRPC